The current study was conducted to determine the effect of postoperative radiotherapy (PORT) on overall survival in patients with surgically managed pT3-T4aN0 laryngeal squamous cell carcinoma (SCC). METHODS: A review of the National Cancer Data Base from 2004 through 2013 was performed. Patients with surgically managed pT3-4aN0 laryngeal SCC with negative surgical margins were included. Univariable and multivariable Cox regression analyses were used to determine factors associated with survival. RESULTS: A total of 1460 patients were included, 46.2% of whom had pT3N0 disease (674 patients) and 53.8% of whom had pT4aN0 disease (786 patients). Approximately 72.0% of the patients with pT3N0 disease (485 patients) and 50.1% of the patients with pT4aN0 disease (394 patients) received PORT. PORT was not found to be associated with improved overall survival on univariable analysis for patients with pT3N0 disease (hazard ratio [HR], 0.84; 95% confidence interval [95% CI], 0.62-1.14), but was for patients with pT4aN0 disease (HR, 0.57; 95% CI, 0.45-0.71). For patients with pT3N0 SCC of the larynx, in a multivariable Cox regression analysis adjusting for age >65 years, severity of comorbidities, larynx subsite, extent of laryngectomy, and number of lymph nodes removed, PORT was not found to be associated with improved survival (adjusted HR, 0.88; 95% CI, 0.64-1.21). For patients with pT4aN0 disease, the administration of PORT was associated with improved survival on multivariable analysis adjusting for age >65 years, severity of comorbidities, larynx subsite, number of lymph nodes removed, and type of hospital (adjusted HR, 0.58; 95% CI, 0.46-0.73). CONCLUSIONS: For patients with surgically managed pT3N0 laryngeal SCC with negative margins, PORT does not appear to be associated with improved survival. Despite a survival benefit, nearly 50% of patients with pT4aN0 laryngeal SCC and negative surgical margins do not receive standard-of-care PORT.
INTRODUCTION
The optimal treatment of patients with locally advanced squamous cell carcinoma (SCC) of the larynx remains controversial. [1] [2] [3] [4] For patients with locally advanced disease, nonsurgical options require multimodality therapy involving some combination of both chemotherapy and radiotherapy (RT). 5, 6 For patients who undergo primary surgical management, the optimal adjuvant therapy within the setting of locally advanced, lymph node-negative disease is to our knowledge not known. [7] [8] [9] [10] For patients with surgically managed glottic and supraglottic SCC without regional metastases, the National Comprehensive Cancer Network (NCCN) treatment guidelines (version 2.2016) recommend postoperative RT (PORT) for patients with pT4 disease, perineural invasion (PNI), or vascular embolism. 6 However, other guidelines recommend PORT for patients with pT3 and pT4 laryngeal SCC. The "treatment-related quality of care measures" approved by the Executive Council of the American Head and Neck Society recommend that patients with pT3 and pT4 laryngeal cancer be referred for consideration of RT. 11 The American College of Radiology appropriateness criteria for adjuvant therapy for patients with resected head and neck SCC recommend PORT for all patients with T3/4 SCC of the larynx. 12 In large clinical trials, patients with T3N0 laryngeal SCC often receive PORT. 13, 14 In published surgical case series of surgically managed patients with locally advanced laryngeal SCC, the administration of PORT is heterogeneous and its relationship with improved oncologic outcomes is unclear. 9, [15] [16] [17] Given the uncertainty surrounding the appropriate adjuvant therapy for patients with pT3N0 and pT4aN0 SCC of the larynx, we sought to answer the question of whether PORT is associated with improved survival in surgically managed patients with pT3N0 or pT4aN0 laryngeal SCC with negative margins.
MATERIALS AND METHODS

Data Source
The National Cancer Data Base (NCDB) is a hospitalbased cancer registry that is a joint program of the American College of Surgeons Commission on Cancer and the American Cancer Society. The NCDB annually collects high-quality and internally appraised cancer data from >1500 Commission on Cancer-accredited hospitals in the United States. As such, it captures approximately 70% of all cancer diagnoses in the United States (>1 million unique cancer cases annually), making it to our knowledge the world's largest clinical cancer registry. 18 
Study Cohort
The Medical University of South Carolina Institutional Review Board deemed this study exempt from review. Primary laryngeal malignancies were filtered using International Classification of Disease for Oncology, 3rd Edition site codes for laryngeal cancer (C32.0-3, C32.8, and C32.9). The NCDB was reviewed from 2004 through 2013 for patients with pT3/T4aN0M0 laryngeal SCC who underwent definitive surgery; a total of 2725 patients met these inclusion criteria. The study was limited to patients with pN0 disease to avoid the additional uncertainty regarding the role of PORT for patients with pN1 disease and adjuvant chemoradiation for patients with pN1 disease with extracapsular spread. 6 The inclusion and exclusion criteria for the study cohort are listed in Figure 1 . Information regarding the number of lymph nodes examined is available in the NCDB but the laterality and extent of neck dissection are not collected, nor is information concerning the RT fields. Patients were staged according to the sixth or seventh edition of the American Joint Committee on Cancer staging system depending on the year of diagnosis.
Outcome Measures
The primary outcome measure was overall survival (OS), which was calculated as the time from the date of diagnosis until the date of death or last follow-up. Tumor registrars report patient follow-up to the NCDB annually and Commission on Cancer accreditation standards require an annual 90% follow-up rate for all living analytic patients. Neither patterns of failure nor disease-specific survival are available in the NCDB.
Study Variables
Independent variables analyzed included patient sociodemographic characteristics (age, sex, race, and insurance status), comorbidity, oncologic characteristics (laryngeal subsite, pathologic T classification, and tumor grade), treatment data (extent of laryngeal surgery, number of lymph nodes removed, adjuvant RT, and adjuvant chemotherapy), and information regarding the structure of care delivery (treatment facility type and US regional location). Comorbidity was assessed with the Charlson/Deyo Comorbidity Score and categorized as 0, 1, or 2 in the NCDB. Extent of surgery was categorized as partial or total laryngectomy. The number of lymph nodes removed was dichotomized into <18 lymph nodes and 18 lymph nodes based on prior studies evaluating the prognostic significance of 18 lymph nodes in patients with head and neck cancer. 19, 20 Tumor grade is available in the NCDB and grade 3 ("poorly differentiated") and grade 4 ("undifferentiated/anaplastic") tumors were grouped together. PNI is not recorded in the NCDB. Lymphovascular invasion is a variable within the NCDB, but was unknown for 68.8% of patients in the current data set (1004 of 1460 patients) and therefore was not analyzed. Treatment facility type is classified in the NCDB as community cancer programs, comprehensive community cancer programs, integrated network cancer programs, and academic programs (training residents in at least 4 specialties is required). Nonacademic facility types are differentiated based on annual case volume for all cancers (community vs comprehensive community) or whether they belong to a network of facilities that provide integrated and comprehensive cancer care (integrated network). 21 
Statistical Analysis
Pearson chi-square tests were used to assess for associations between categorical variables and treatment modality. Kaplan-Meier estimates of survival were used to Abbreviations: 95% CI, 95% confidence interval; Gy, grays; NA, not applicable; NOS, not otherwise specified; PORT, postoperative radiotherapy. a Certain rows/columns may not sum to the total in cases in which one of the categorical variables had a cell size <10 to protect patient identity as per National Cancer Data Base policy.
Original Article compare unadjusted survival time distributions for patients with and without adjuvant RT for pT3 and pT4a tumors. To assess the relationship between PORT and OS, univariable and multivariable Cox proportional hazards regression analyses were performed to adjust for confounders and to identify factors independently associated Abbreviations: 95% CI, 95% confidence interval; Gy, grays; NA, not applicable; NOS, not otherwise specified; PORT, postoperative radiotherapy; RT, radiotherapy. a Certain rows/columns may not sum to the total in cases in which one of the categorical variables had a cell size <10 to protect patient identity as per National Cancer Data Base policy.
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June 15, 2017 with improved survival. The proportional hazards assumption was verified using log-minus-log plots. Variables significant at an a level of .10 with perceived clinical relevance were entered into the final Cox multivariable logistic regression model. For collinear variables, clinical relevance was used. A landmark analysis was performed to assess for potential confounding by the immortal time bias. If the intention was to treat a patient with PORT but the patient experienced a perioperative death before the initiation of PORT, it would appear that the patient belonged in the "surgery-only" group despite the intent to provide PORT. This effect can bias survival estimates in favor of adjuvant RT over no adjuvant RT in database studies when the treatment intention is not known. 22, 23 To assess for potential immortal time bias, a landmark time frame of 3 months was selected. 1 A total of 25 patients died within 3 months of undergoing surgery. All survival analyses were repeated and the conclusions were found to be unaffected (data not shown).
Data analysis was performed using SPSS statistical software (version 23; IBM Corporation, Armonk, NY). All tests were 2-sided with a P value of < .05 considered to be statistically significant.
RESULTS
Patient Characteristics
We identified 1460 patients who met the study inclusion criteria. Of these, 46.2% had pT3N0 disease (674 patients) and 53.8% had pT4aN0 disease (786 patients). The patient, oncologic, and treatment characteristics of the pT3N0 cohort are presented in Table 1 . Of the patients with pT3N0 disease, 42.3% (285 patients) had SCC of the supraglottic larynx and 34.4% (232 patients) had SCC of the glottic larynx, whereas the remaining patients had SCC of the subglottis; trans-glottis; or larynx, not otherwise specified. For patients with pT3N0 SCC of the larynx, there was a low rate of discordance between clinical and pathologic T and N classifications as 20.0% of patients were classified as having either cT1-2 or T4 disease (135 patients) and 11.0% were classified as clinically N positive (74 patients). Nearly 17% of these 674 patients (113 patients) underwent either open or endoscopic larynx-preserving surgery and 80% of patients (540 patients) underwent total laryngectomy. Approximately 24% of the patients with pT3N0 disease (159 patients) received PORT. Patients who were less likely to receive PORT included those aged >65 years, those who had Medicare insurance, and those treated at an academic medical center.
Of the patients with pT4aN0 disease (Table 2) , SCC of the glottic larynx was more common (41.7%; 328 patients) than SCC of the supraglottic larynx (21.6%; 170 patients). There was a low rate of discordance between clinical and pathologic T and N classifications for patients with T4aN0 disease, as 16.2% of patients were classified as having cT1-3 disease (128 patients) and 11.0% were classified as clinically N positive (86 patients). Nearly all patients (93.5%; 735 patients) underwent a total laryngectomy and 50.1% of patients (394 patients) received PORT. Patients who were less likely to receive PORT included those aged >65 years, those with more severe comorbidities, and those treated at an academic medical center.
Effect of PORT on OS for Patients With pT3N0 Disease
For patients with pT3N0 SCC of the larynx, the unadjusted 5-year OS rate was 66.2% (70.0% for patients receiving PORT and 64.7% for patients not receiving PORT). Kaplan-Meier analysis (Fig. 2) did not demonstrate improved OS with PORT (log-rank P 5 .259). The results of the univariable and multivariable Cox regression analyses for patients with pT3N0 disease are shown in Table 3 . For patients with pT3N0 disease, age 65 years, increasing severity of comorbidities, Medicare insurance, tumor location in the glottis, removal of <18 lymph nodes, and performance of total laryngectomy were found to be associated with decreased OS on univariable analysis. The addition of PORT did not improve survival (unadjusted hazard ratio [HR], 0.84; 
Effect of PORT on OS for Patients With pT4aN0 Disease
For patients with surgically managed pT4aN0 laryngeal cancer, the 5-year OS rate was 59.7% (67.5% for patients who received PORT and 52.1% for those who did not). As seen in Figure 3 , patients with pT4aN0 SCC of the larynx had improved OS with the addition of PORT (logrank P<.001). Factors found to be associated with improved survival on univariable and multivariable Cox regression analyses are shown in Table 4 . Age 65 years, increasing severity of comorbidities, and Medicare insurance were found to be associated with decreased survival. Patients who received PORT were found to have a 40% decrease in their risk of death on univariable analysis (unadjusted HR, 0.57; 95% CI, 0.45-0.71). Treatment at an academic medical center also was associated with improved survival on univariable analysis (unadjusted HR, 0.58; 95% CI, 0.39-0.87). On multivariable Cox regression analysis adjusting for age 65 years, severity of comorbidities, larynx subsite, number of lymph nodes removed, and type of treating facility, the addition of PORT remained associated with improved OS (adjusted HR, 0.58; 95% CI, 0.46-0.73).
DISCUSSION
The debate regarding the optimal treatment for patients with locally advanced laryngeal cancer has focused on Abbreviations: 95% CI, 95% confidence interval; Gy, grays; HR, hazard ratio; NOS, not otherwise specified; PORT, postoperative radiotherapy; RT, radiotherapy.
strategies that maximize laryngeal function without compromising oncologic outcomes. 24 For surgically managed patients, the optimal adjuvant therapy for those with locally advanced, lymph node-negative SCC of the larynx remains uncertain. [6] [7] [8] [9] [10] [11] [12] 15 To help answer this unresolved question, we used the NCDB to examine whether the addition of PORT improved survival in patients with margin-negative, surgically managed, pT3N0 and pT4aN0 SCC of the larynx. We found that PORT did not improve survival for patients with pT3N0 disease, but did for those with pT4aN0 disease.
pT3N0 SCC of the Larynx
In the current study, the addition of PORT was not found to be associated with increased survival for patients with pT3N0 laryngeal SCC on either univariable or multivariable analysis. The lack of benefit of PORT in these patients was noted despite a bias in the study design favoring PORT by excluding those patients who had suboptimal PORT due to excessive delays in the initiation of therapy, treatment breaks causing an increased duration of PORT, or suboptimal total PORT dosing. In addition, although we tried to minimize the effect of immortal time bias analysis, it also could have contributed to an apparent perceived benefit to PORT.
The data indicating that patients with pT3N0 disease do not benefit from PORT are consistent with the previously published, albeit limited, single-institution studies that similarly suggested no survival benefit for these patients. 9, 15 If patients with pT3N0 SCC of the larynx do not have increased survival with the addition of PORT, they then potentially could be treated with singlemodality therapy without a decrement in oncologic outcomes. The omission of PORT is associated with a decrease in long-term morbidity as well as a significant improvement in functional outcomes for these patients. 25 Prior studies have described a 5% to 10% rate of severe late laryngeal complications with PORT for patients who retain a larynx after surgery, including chondroradionecrosis of the larynx and laryngeal stenosis, and complications such as pharyngoesophageal stenosis also affect those individuals undergoing total laryngectomy. 10, 26 Although data regarding disease recurrence and disease-specific survival are lacking in the current study, if future studies confirm that patients with T3N0 SCC of the larynx may be treated with single-modality surgical therapy in an oncologically sound fashion, this information might help inform decision making in the preoperative setting when the patient is choosing between surgical and nonsurgical treatment paradigms. The nonsurgical alternative (concurrent chemoradiation-based approaches) has significant associated morbidity, including a 33% rate of severe late toxicity, a rate of pharyngeal dysfunction of 17% to 25%, and a treatment protocol-associated mortality rate of 7%. 5, 27, 28 In addition, there also may be a survival benefit to a primary surgical approach among patients with T3 glottic cancer because one study using the Surveillance, Epidemiology, and End Results program to compare the surgical and nonsurgical management of such patients found an increase in OS with a primary surgical strategy, regardless of whether patients received postoperative RT. 29 Because the current study did not compare surgical and nonsurgical alternatives for patients with T3N0 SCC of the larynx, future studies comparing the oncologic and functional outcomes of different management strategies will be required. Other high-risk features such as PNI, transglottic tumors, high tracheostomy with at-risk stomal margins, and an aggressive growth pattern may be exceptions for which individual decisions need to be made.
pT4aN0 SCC of the Larynx
Patients with pT4aN0 SCC of the larynx who underwent surgery with negative margins do appear to benefit from PORT, because it was found to be associated with a nearly 40% decrease in the risk of death on both univariable and multivariable analyses in the current study. In small single-institution studies, it sometimes is questioned whether patients with pT4aN0 SCC of the larynx benefit from the addition of PORT. 9, 15 However, the omission of PORT in this setting is contrary to current published recommendations from the NCCN and the American Head and Neck Society, 6, 11, 12 and not supported by data from the current study. The apparent uncertainty regarding the benefit of PORT in these patients is demonstrated in the current study, because nearly 50% of patients with pT4aN0 SCC of the larynx did not receive the recommended PORT.
Variability in the Administration of PORT
There appears to be a significant variability in the intention to treat and administration of PORT in patients with locally advanced, margin-negative, lymph node-negative, SCC of the larynx who are undergoing surgery. Nearly 50% of the patients in the pT4aN0 cohort in the current study, for whom PORT is recommended by NCCN guidelines, 6 did not receive it. This represents a large number of patients who are not receiving the standard of care. Certain patient factors were found to be associated with the likelihood of receiving adjuvant RT. Not surprisingly, elderly patients and patients with more severe comorbidities were found to be less likely to receive adjuvant RT. However, what was less expected was that patients treated at academic medical centers were less likely to receive recommended PORT compared with those treated at community cancer hospitals. Further research will be required to understand the reasons why such a large number of patients with pT4aN0 SCC of the larynx do not receive standard-of-care adjuvant RT after surgical resection. This may be related to regional practice patterns, distance from a tertiary care center, patient comorbidities, or tumor factors not apparent in the TNM staging.
Conversely, nearly 25% of the patients with pT3N0 SCC of the larynx, for whom no survival benefit was noted in the current study, did receive PORT. Although there is incomplete information related to the presence or absence of adverse features such as PNI or the extent and laterality of neck dissections, these patients are potentially being overtreated and being exposed to additional morbidity and a decrement in their quality of life without an increase in survival. Similar to what was observed for patients with pT4aN0 SCC of the larynx, patient-related factors such as younger age and lack of comorbidities were found to be associated with an increased likelihood of receiving adjuvant therapy. This might represent the belief that these patients are young and healthy can "handle" the challenge of RT. If there is no survival benefit to adding RT, this practice should be brought into question because the younger and healthier patients also are those who will have to live the longest with the burden of long-term radiation toxicity. Further study will be required to determine whether this variability in practice patterns is driven by patient factors, hospital factors, or differences in regional practice patterns.
Limitations
The current study has several limitations. Because it is a retrospective database study, we did not have knowledge of certain tumor characteristics that might affect treatment decisions such as cartilage invasion, subglottic extent, or the presence of pulmonary nodules. We did not know the extent of preoperative staging evaluation such as positron emission tomography/computed tomography or certain treatment-related details such as the laterality or extent of the neck dissections or RT fields. Adverse pathologic features such as PNI or lymphovascular space invasion are not systematically recorded in the NCDB, thereby limiting our analysis for these subsets of patients. Despite the lack of information regarding PNI in the current study, it is unclear whether PORT improves survival in patients for whom the only indication for PORT is PNI. 30 The effect of adjuvant RT on patterns of failure, disease-specific survival, and disease-free survival could not be determined in the current study because only information regarding OS is available in the NCDB. The effect of PORT on these outcome measures should be evaluated in future studies. Despite these limitations, there are numerous methodological strengths to the current study. It captures patients of all adult ages, has a national scope and a large sample size, and analyzes treatment at different types of hospitals.
Conclusions
For patients with surgically managed pT3N0 SCC of the larynx who undergo a negative-margin surgical resection, PORT does not appear to be associated with improved OS and these patients may be considered for singlemodality therapy without a decrement in OS. Patients with pT4aN0 SCC of the larynx and negative surgical margins appear to have improved OS with the addition of adjuvant RT. Significant variability exists in the administration of PORT to these patients that requires further investigation.
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